Showing results (301-310 of 333) with videos related to

Sort By:
Pageof 34
Future Oncology (London, England)|October 15, 2025
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumorsThomas Powles, Aarti Bhatia, Barbara Burtness, et al.
International Journal of Clinical Oncology|May 27, 2026
Quantitative evaluation of healthcare information provided to patients with thoracic malignancies: patient satisfaction survey of the Japan Lung Cancer SocietyTakayuki Takahama, Hidefumi Shimizu, Kenichi Yoshimura, et al.
The Oncologist|December 16, 2020
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid TumorsMasayuki Takeda, Takayuki Takahama, Kazuko Sakai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2023
Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, et al.
Cancer Science|February 2, 2026
Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With AtezolizumabAtsuto Mouri, Hiroshi Kagamu, Koji Tamada, et al.
British Journal of Cancer|March 23, 2024
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancerKoji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, et al.
Cancer Discovery|September 22, 2021
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung CancerPasi A Jänne, Christina Baik, Wu-Chou Su, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 1, 2025
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLCPasi A Jänne, Yasushi Goto, Toshio Kubo, et al.
Nature Cancer|May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trialSolange Peters, Daniel S W Tan, David E Gerber, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief ReportHidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.
Pageof 34